The coronavirus outbreak has generated a significant repercussion on the administration of adoptive cell therapies, including chimeric antigen receptor (CAR) T-cells. Decline in people transit, closing of borders, and confinement of the population has impacted the supply chains of these life-saving medical products. This is anticipated to slowdown the growth of the CAR T-cell therapy market during the ongoing pandemic.
Although hospitals have been compelled to change their usual workflows to cope with the saturation of health services by hospitalized patients, stakeholders in the CAR T-cell therapy market are increasing efforts to ensure continuity in offering the treatment. This is prominent in the case of patients with relapsed/refractory hematologic malignancies. Moreover, the burgeoning growth of telehealth services is encouraging early intervention to attenuate neurotoxicity or cytokine release syndrome with tocilizumab and prophylactic/preventive strategies to prevent infection.
The CAR T-cell therapy market is expected to clock a CAGR of 30.6% during the assessment period. The CAR T-cell therapy is known as a revolutionary treatment option for cancer, owing to its remarkably effective and durable clinical responses. However, market stakeholders need to address major limitations to the CAR T-cell therapy, which involves life-threatening CAR T-cell associated toxicities, limited persistence, and issues such as low efficacy against solid tumors. Hence, stakeholders are increasing their research capabilities to combine the CAR T-cell therapy with other anticancer therapies.
Stakeholders in the CAR T-cell therapy market are anticipated to collaborate with researchers, scientists, and biotechnologists to employ innovative CAR engineering strategies in order to improve anti-tumor efficacy, expand clinical efficacy, and limit toxicities. Stakeholders are increasing efforts to improve clinical efficacy in both hematological malignancy and solid tumors to overcome treatment limitations.
Several hundred clinical trials of CAR-T have been registered and actively recruiting patients with various malignant & non-malignant conditions are showing rapid pace of innovation in this field. However, substantial challenges currently limit its widespread adoption. The CAR T-cell therapy is potentially expensive with both tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) in the U.S. when used for high-grade B-cell lymphomas. Hence, stakeholders in the CAR T-cell therapy market are increasing efforts to reduce cost in order to meet the expanding indications of CAR-T.
Publically funded healthcare systems where resource allocation is strained, healthcare providers are striving to reduce treatment cost for CAR-T. Companies in the CAR T-cell therapy market are gaining awareness about novel strategies such as in vivo gene delivery to immune cells using nanoparticles to improve medical outcomes.
The CAR T-cell therapy market is projected to mature from a revenue of US$ 1.1 Bn in 2020 and reach US$ 21.8 Bn by 2031. From regulatory point of view, CAR T-cells are an advanced therapy medicinal product (ATMP) in the European Union (EU). Companies are increasing the availability of tissue-engineered products, gene therapy medicinal products, and somatic cell therapy medicinal products, among others. Such products are playing a crucial role in the treatment of cancer and hereditary diseases as well as in regenerative medicine.
CAR T-cells as an ATMP can be generated by either viral transduction, leading to a permanent CAR expression or by using mRNA. Companies in the CAR T-cell therapy market are increasing R&D investments in this field of the study. Manufacturing, approvals, and regulations of these therapies are potentially complex to protect patients.
The immunotherapy industry is an ever-evolving landscape with interest in CAR T-cells, checkpoint inhibitors, and bispecific antibodies exploding in the recent years. Likewise, Ceylad Oncology - a clinical stage biotechnology company, is gaining recognition for increasing its focus on CAR T-cell therapies, which involve engineering patient or donor T cells to display a CAR that targets the immune cells to cancer cells via antigen receptor binding. Such innovations are helping healthcare providers to treat new and difficult cancer indications, including solid tumors, and harness the immune system in a novel way to target new pathways.
Companies in the CAR T-cell therapy market are mainly focusing on immunotherapies that are showing potential in standalone treatments and in administration in combination with other types of treatments.
The CAR T-cell therapy is emerging as a breakthrough innovation in cancer treatment. Clinical trials conducted globally are showing promising results in end stage patients and especially, for patients suffering from Acute Lymphocytic Leukemia. Such findings are translating into revenue opportunities for companies in the CAR T-cell therapy market. However, there is a need to increase the availability of CAR T-cell therapy in India. A possible way to increase its availability in India is by reducing the cost of the treatment.
The manufacturing complexity is a major reason for high therapy cost in India. In order to promote and support the development of CAR T-cell technology against cancer and other diseases, the Biotechnology Industry Research Assistance Council (BIRAC) is taking the initiative to invite proposals in India.
Since medicine continues to be revolutionized by advancements in treatments, CAR T-cell therapies are achieving increased commercialization. Such trends are contributing to the growth of the global CAR T-cell therapy market. For instance, Anixa Biosciences, Inc. is being known for its therapeutics profile in a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T.
CAR T-cell therapies are subject to health and research policy frameworks as well as legal regulations that have a direct influence on international competitiveness. Companies in the CAR T-cell therapy market are adhering to this design framework, which is an important instrument to support research in the EU and to promote innovations. It has been found that there are strict regulations in Germany for the import of medicinal products in order to ensure patient safety.
Analysts’ Viewpoint
Apart from gene therapy medicinal products, CAR T-cells holds promising potentials in the development of therapies for viral infections such as coronavirus. However, the high cost of CAR T-cell therapy in India is affecting market growth. Hence, companies in the India CAR T-cell therapy market should work closely with BIRAC and the Department of Biotechnology (DBT) to develop this technology in a cost effective manner whilst making it increasingly available for patients. The Tata Memorial Hospital (TMH), IIT Bombay team, and cancer care in India are gaining popularity for conducting the first CAR T-cell therapy at the bone marrow transplant unit at ACTREC, Tata Memorial Center in Mumbai.
Major Players
|
Attribute |
Detail |
|
Market Size Value in 2020 (Base Year) |
US$ 1.1 Bn |
|
Market Forecast Value in 2031 |
US$ 21.8 Bn |
|
Growth Rate (CAGR) |
30.6% |
|
Forecast Period |
2021–2031 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, parent industry overview, etc. |
|
Competition Landscape |
Company Profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, key financials, etc. |
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
CAR T-cell Therapy Market – Segmentation
TMR’s study on the global CAR T-cell therapy market includes information divided into four segments: product type, indication, end-user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global CAR T-cell therapy market are discussed in detail.
| Product Type |
|
| Indication |
|
| End-user |
|
| Region |
|
CAR T-cell therapy market to reach valuation Of US$ 21.8 Bn by 2031
CAR T-cell therapy market is expected to clock a CAGR of 30.6% from 2021 to 2031
CAR T-cell therapy market is driven by increase in incidence of cancer and strong product pipeline
North America dominated the global CAR T-cell therapy market in 2020 and the trend is anticipated to continue during the forecast period
Key players operating in the global market include Pfizer, Inc., Novartis AG, Bristol-Myers Squibb, Amgen, Inc., Sorrento Therapeutics, Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and bluebird bio, Inc.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global CAR T-cell Therapy Market Forecast
4.4. Global CAR T-cell Therapy Market Outlook
5. Market Outlook
5.1. Key Industry Events
5.2. Diseases Epidemiology
5.3. Product Pipeline Analysis
5.4. Impact of COVID-19 Pandemic
6. Global CAR T-cell Therapy Market Analysis, by Product Type
6.1. Introduction
6.2. Global CAR T-cell Therapy Market Value Share Analysis, by Product Type
6.3. Global CAR T-cell Therapy Market Forecast, by Product Type
6.3.1. Axicabtagene Ciloleucel
6.3.2. Tisagenlecleucel
6.3.3. Brexucabtagene Autoleucel
6.3.4. Lisocabtagene Maraleucel
6.3.5. Idecabtagene Vicleucel
6.3.6. Others
6.4. Global CAR T-cell Therapy Market Analysis, by Product Type
6.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Product Type
7. Global CAR T-cell Therapy Market Analysis, by Indications
7.1. Introduction
7.2. Global CAR T-cell Therapy Market Value Share Analysis, by Indication
7.3. Global CAR T-cell Therapy Market Forecast, by Indication
7.3.1. Acute Lymphocytic Leukemia
7.3.2. Diffuse Large B-Cell Lymphoma
7.3.3. Follicular Lymphoma
7.3.4. Mantle Cell Lymphoma
7.3.5. Multiple Myeloma
7.3.6. Others
7.4. Global CAR T-cell Therapy Market Analysis, by Indication
7.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Indication
8. Global CAR T-cell Therapy Market Analysis, by End-user
8.1. Introduction
8.2. Global CAR T-cell Therapy Market Value Share Analysis, by End-user
8.3. Global CAR T-cell Therapy Market Forecast, by End-user
8.3.1. Hospitals
8.3.2. Cancer Treatment Centers
8.4. Global CAR T-cell Therapy Market Analysis, by End-user
8.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by End-user
9. Global CAR T-cell Therapy Market Analysis, by Region
9.1. Global CAR T-cell Therapy Market Analysis, by Region
9.2. Global CAR T-cell Therapy Market Value Share Analysis, by Region
9.3. Global CAR T-cell Therapy Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America CAR T-cell Therapy Market Analysis
10.1. North America CAR T-cell Therapy Market Overview
10.2. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country
10.3. North America CAR T-cell Therapy Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
10.5. North America CAR T-cell Therapy Market Forecast, by Product Type
10.5.1. Axicabtagene Ciloleucel
10.5.2. Tisagenlecleucel
10.5.3. Brexucabtagene Autoleucel
10.5.4. Lisocabtagene Maraleucel
10.5.5. Idecabtagene Vicleucel
10.5.6. Others
10.6. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indications
10.7. North America CAR T-cell Therapy Market Forecast, by Indication
10.7.1. Acute Lymphocytic Leukemia
10.7.2. Diffuse Large B-Cell Lymphoma
10.7.3. Follicular Lymphoma
10.7.4. Mantle Cell Lymphoma
10.7.5. Multiple Myeloma
10.7.6. Others
10.8. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
10.9. North America CAR T-cell Therapy Market Forecast, by End-user
10.9.1. Hospitals
10.9.2. Cancer Treatment Centers
11. Europe CAR T-cell Therapy Market Analysis
11.1. Europe CAR T-cell Therapy Market Overview
11.2. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe CAR T-cell Therapy Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
11.5. Europe CAR T-cell Therapy Market Forecast, by Product Type
11.5.1. Axicabtagene Ciloleucel
11.5.2. Tisagenlecleucel
11.5.3. Brexucabtagene Autoleucel
11.5.4. Lisocabtagene Maraleucel
11.5.5. Idecabtagene Vicleucel
11.5.6. Others
11.6. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
11.7. Europe CAR T-cell Therapy Market Forecast, by Indication
11.7.1. Acute Lymphocytic Leukemia
11.7.2. Diffuse Large B-Cell Lymphoma
11.7.3. Follicular Lymphoma
11.7.4. Mantle Cell Lymphoma
11.7.5. Multiple Myeloma
11.7.6. Others
11.8. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
11.9. Europe CAR T-cell Therapy Market Forecast, by End-user
11.9.1. Hospitals
11.9.2. Cancer Treatment Centers
12. Asia Pacific CAR T-cell Therapy Market Analysis
12.1. Asia Pacific CAR T-cell Therapy Market Overview
12.2. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific CAR T-cell Therapy Market Forecast, by Country/Sub-region
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
12.5. Asia Pacific CAR T-cell Therapy Market Forecast, by Product Type
12.5.1. Axicabtagene Ciloleucel
12.5.2. Tisagenlecleucel
12.5.3. Brexucabtagene Autoleucel
12.5.4. Lisocabtagene Maraleucel
12.5.5. Idecabtagene Vicleucel
12.5.6. Others
12.6. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
12.7. Asia Pacific CAR T-cell Therapy Market Forecast, by Indication
12.7.1. Acute Lymphocytic Leukemia
12.7.2. Diffuse Large B-Cell Lymphoma
12.7.3. Follicular Lymphoma
12.7.4. Mantle Cell Lymphoma
12.7.5. Multiple Myeloma
12.7.6. Others
12.8. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
12.9. Asia Pacific CAR T-cell Therapy Market Forecast, by End-user
12.9.1. Hospitals
12.9.2. Cancer Treatment Centers
13. Latin America CAR T-cell Therapy Market Analysis
13.1. Latin America CAR T-cell Therapy Market Overview
13.2. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America CAR T-cell Therapy Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
13.5. Latin America CAR T-cell Therapy Market Forecast, by Product Type
13.5.1. Axicabtagene Ciloleucel
13.5.2. Tisagenlecleucel
13.5.3. Brexucabtagene Autoleucel
13.5.4. Lisocabtagene Maraleucel
13.5.5. Idecabtagene Vicleucel
13.5.6. Others
13.6. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
13.7. Latin America CAR T-cell Therapy Market Forecast, by Indication
13.7.1. Acute Lymphocytic Leukemia
13.7.2. Diffuse Large B-Cell Lymphoma
13.7.3. Follicular Lymphoma
13.7.4. Mantle Cell Lymphoma
13.7.5. Multiple Myeloma
13.7.6. Others
13.8. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
13.9. Latin America CAR T-cell Therapy Market Forecast, by End-user
13.9.1. Hospitals
13.9.2. Cancer Treatment Centers
14. Middle East & Africa CAR T-cell Therapy Market Analysis
14.1. Middle East & Africa CAR T-cell Therapy Market Overview
14.2. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa CAR T-cell Therapy Market Forecast, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
14.5. Middle East & Africa CAR T-cell Therapy Market Forecast, by Product Type
14.5.1. Axicabtagene Ciloleucel
14.5.2. Tisagenlecleucel
14.5.3. Brexucabtagene Autoleucel
14.5.4. Lisocabtagene Maraleucel
14.5.5. Idecabtagene Vicleucel
14.5.6. Others
14.6. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
14.7. Middle East & Africa CAR T-cell Therapy Market Forecast, by Indication
14.7.1. Acute Lymphocytic Leukemia
14.7.2. Diffuse Large B-Cell Lymphoma
14.7.3. Follicular Lymphoma
14.7.4. Mantle Cell Lymphoma
14.7.5. Multiple Myeloma
14.7.6. Others
14.8. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
14.9. Middle East & Africa CAR T-cell Therapy Market Forecast, by End-user
14.9.1. Hospitals
14.9.2. Cancer Treatment Centers
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles
15.2.1. Pfizer Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. Financial Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Novartis AG
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. Financial Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Bristol-Myers Squibb
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. Financial Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Amgen, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Sorrento Therapeutics, Inc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. Financial Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Johnson & Johnson Services, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Financial Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Gilead Sciences, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. Financial Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Merck & Co., Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. Financial Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. bluebird bio, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Financial Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
List of Tables
Table 01: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 02: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 03: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 07: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 08: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 11: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 12: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 15: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 16: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 19: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 20: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 23: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 24: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global CAR T-cell Therapy Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global CAR T-cell Therapy Market Value Share, by Product Type, 2020
Figure 03: Global CAR T-cell Therapy Market Value Share, by Indication, 2020
Figure 04: Global CAR T-cell Therapy Market Value Share, by End-user Type, 2020
Figure 05: Global CAR T-cell Therapy Market Value Share, by Region, 2020
Figure 06: Global Car T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 07: Global Car T-Cell Therapy Market Value (US$ Mn), by Axicabtagene Ciloleucel, 2017–2031
Figure 08: Global Car T-Cell Therapy Market Value (US$ Mn), by Tisagenlecleucel, 2017–2031
Figure 09: Global Car T-Cell Therapy Market Value (US$ Mn), by Brexucabtagene Autoleucel, 2017–2031
Figure 10: Global Car T-Cell Therapy Market Value (US$ Mn), by Lisocabtagene Maraleucel, 2017–2031
Figure 11: Global Car T-Cell Therapy Market Value (US$ Mn), by Idecabtagene Vicleucel, 2017–2031
Figure 12: Global Car T-Cell Therapy Market Value (US$ Mn), by Others, 2017–2031
Figure 13: Global Car T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 14: Global Car T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031
Figure 15: Global Car T-Cell Therapy Market Value (US$ Mn), by Acute Lymphocytic Leukemia, 2017–2031
Figure 16: Global Car T-Cell Therapy Market Value (US$ Mn), by Diffuse Large B-cell Lymphoma, 2017–2031
Figure 17: Global Car T-Cell Therapy Market Value (US$ Mn), by Follicular Lymphoma, 2017–2031
Figure 18: Global Car T-Cell Therapy Market Value (US$ Mn), by Mantle Cell Lymphoma, 2017–2031
Figure 19: Global Car T-Cell Therapy Market Value (US$ Mn), by Multiple Myeloma, 2017–2031
Figure 20: Global Car T-Cell Therapy Market Value (US$ Mn), by Others, 2017–2031
Figure 21: Global Car T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031
Figure 22: Global Car T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031
Figure 23: Global Car T-Cell Therapy Market Value (US$ Mn), by Hospitals, 2017–2031
Figure 24: Global Car T-Cell Therapy Market Value (US$ Mn), by Cancer Treatment Centers, 2017–2031
Figure 25: Global Car T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031
Figure 26: Global Car T-Cell Therapy Market Value Share Analysis, by Region, 2020 and 2031
Figure 27: Global Car T-Cell Therapy Market Attractiveness Analysis, by Region, 2021-2031
Figure 28: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 29: North America CAR T-Cell Therapy Market Value Share (%), by Country, 2020 and 2031
Figure 30: North America CAR T-Cell Therapy Market Attractiveness Analysis, by Country, 2021–2031
Figure 31: North America CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 32: North America CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 33: North America CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031
Figure 34: North America CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031
Figure 35: North America CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031
Figure 36: North America CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031
Figure 37: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 38: Europe CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 39: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 40: Europe CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 41: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 42: Europe CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031
Figure 43: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031
Figure 44: Europe CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031
Figure 45: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031
Figure 46: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 47: Asia Pacific CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 48: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 49: Asia Pacific CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 50: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 51: Asia Pacific CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031
Figure 52: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031
Figure 53: Asia Pacific CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031
Figure 54: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031
Figure 55: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 56: Latin America CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 57: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 58: Latin America CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 59: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 60: Latin America CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031
Figure 61: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031
Figure 62: Latin America CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031
Figure 63: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031
Figure 64: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 65: Middle East & Africa CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 66: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 67: Middle East & Africa CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 68: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 69: Middle East & Africa CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031
Figure 70: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031
Figure 71: Middle East & Africa CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031
Figure 72: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031
Figure 73: Pfizer, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 74: Pfizer, Inc., Breakdown of Net Sales (%), by Biopharma Segment, 2020
Figure 75: Pfizer, Inc., Breakdown of Net Sales (%) Region/Country, 2020
Figure 76: Pfizer, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 77: Novartis AG, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 78: Novartis AG, Revenue Breakdown of Net Sales (%), by Business Segment, 202
Figure 79: Novartis AG, Breakdown of Net Sales (%), by Region/Country, 2020
Figure 80: Novartis AG, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 81: Bristol-Myers Squibb, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 –2020
Figure 82: Bristol-Myers Squibb, Breakdown of Net Sales (%), by Region/Country, 2020
Figure 83: Bristol-Myers Squibb, R&D Expenses (US$ Mn) 2017–2020
Figure 84: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020
Figure 85: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2020
Figure 86: Amgen, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020
Figure 87: Sorrento Therapeutics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020
Figure 88: Sorrento Therapeutics, Inc. Breakdown of Net Sales (%), by Business Segment, 2020
Figure 89: Sorrento Therapeutics, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020
Figure 90: Johnson & Johnson Services, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 91: Johnson & Johnson Services, Inc., Breakdown of Net Sales (%), by Business Segment (Pharmaceutical), 2020
Figure 92: Johnson & Johnson Services, Inc., Breakdown of Net Sales (%), by Region/Country, 2020
Figure 93: Johnson & Johnson Services, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth, 2017–2020
Figure 94: Gilead Sciences, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020
Figure 95: Gilead Sciences, Inc., Breakdown of Net Sales (%), by Region/Country, 2020
Figure 96: Gilead Sciences, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020
Figure 97: Merck & Co., Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 98: Merck & Co., Inc., Breakdown of Net Sales (%), by Business Segment, 2020
Figure 99: Merck & Co., Inc., Breakdown of Net Sales (%), by Region/Country, 2020
Figure 100: Merck & Co., Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth, 2017–2020
Figure 101: bluebird bio, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 102: bluebird bio, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth, 2017–2020
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
CAR T-cell Therapy Market Insights, 2021-2031
